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A B S T R A C T
Comprehensive cardiac rehabilitation (CR) is a mainstay of the secondary prevention of cardiovascular 
disease (CVD). In the European Society of Cardiology guidelines, comprehensive cardiovascular reha-
bilitation has the highest class of recommendation and level of evidence as an effective method for 
the treatment of patients with ST-segment elevation myocardial infarction, after myocardial revascu-
larization, with chronic coronary syndrome, for CVD prevention in clinical practice, and in patients with 
heart failure (HF). This document presents an expert opinion of the Cardiac Rehabilitation and Exercise 
Physiology Section of the Polish Cardiac Society concerning the definition, goals, target population, 
organization of rehabilitation services, standard clinical indications, and methods of implementation. 
Moreover, it describes psychosocial risk factors influencing the course of CR and secondary prevention 
of cardiovascular disease in patients undergoing CR.
Comprehensive CR is a process that should be implemented as soon as possible, continued without 
interruption, and should consist of multiple stages. Moreover, it should be tailored to the individual 
clinical situation and should be accepted by the patient and their family, friends, and caregivers. 
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COMPREHENSIVE CARDIAC 
REHABILITATION: DEFINITION, GOALS, 
TARGET POPULATION, AND ORGANIZATION 
OF REHABILITATION SERVICES
In developed countries, cardiovascular disease (CVD) is 
the most common cause of premature death, which, in 
many cases, could be prevented. Primary and secondary 
prevention of CVD, defined as lifestyle modification with 
regular exercise training and optimal pharmacotherapy, is 
a well-established strategy to reduce morbidity, hospital 
readmission, and mortality due to cardiovascular causes. 
Cardiac rehabilitation (CR) is a mainstay of the secondary 
prevention of CVD. In the European Society of Cardiology 
guidelines, comprehensive CR has the highest class of 
recommendation and level of evidence as an effective 
method for the treatment of patients with ST-segment 
elevation myocardial infarction [1], after myocardial revas-
cularization [2], with chronic coronary syndrome (CCS) [3], 
for CVD prevention in clinical practice [4], and in patients 
with heart failure (HF) [5–7]. Patients with acute coronary 
syndrome (ACS), decompensation of HF, and previous car-
diac surgery or percutaneous coronary intervention (PCI) 
should be referred for an early CR program immediately 
after hospitalization. Each week’s delay in CR requires an 
additional month of exercise to obtain the same level of 
health benefit [8, 9]. Priority patient groups that should 
be offered a CR program are presented in Table 1 [10, 11].
Comprehensive CR is defined as a tailored multidis-
ciplinary intervention that includes clinical evaluation 
(medical history, physical examination, functional ex-
amination, questionnaires, laboratory tests, resting and 
exercise electrocardiography [ECG], echocardiography 
and other diagnostic tests if indicated), management and 
modification of cardiovascular risk factors, physical activity 
counseling, prescription of an appropriate exercise train-
ing program, dietary counseling, as well as psychological, 
social, and vocational support [11]. The aim of CR is also 
to optimize pharmacotherapy and cardiac implantable 
electronic devices function (pacemaker, implantable 
cardioverter-defibrillator [ICD], cardiac resynchronization 
pacemaker, ventricular assist devices, etc.), diagnose frail-
ty syndrome, educate patients and their families about 
healthy behavior and first-aid principles, as well as monitor 
rehabilitation outcomes. Currently, the duration of CR in 
European countries ranges from 8 to 24 weeks, and from 
3 to 4 weeks for inpatient programs [11, 12].
In facilities offering CR services, the medical team 
should include a physical therapist, a nurse, and an elect-
roradiology technician in addition to medical doctors. Co-
operation with a psychologist and a dietitian is important, 
which also applies, in larger facilities, to a rehabilitation 
services manager.
Comprehensive CR is a process that should be imple-
mented as soon as possible, continued without interrup-
tion, and should consist of multiple stages. Moreover, it 
should be tailored to the individual clinical situation and 
should be accepted by the patient and their family, friends, 
and caregivers. 
The CR intervention can be divided into early CR (phas-
es I and II) and late CR (phase III). 
Early comprehensive cardiac rehabilitation: 
phase I
Phase I CR begins during hospitalization for a cardiovascu-
lar event and is provided in an intensive care room or a post-
operative, cardiology, internal medicine, or CR wards. This 
phase should start on admission to the hospital and should 
last until the patient is stable and can be discharged from 
the acute ward. The main goal of phase I is for the patient 
to achieve independence and self-care in performing daily 
activities, to prevent complications of immobility, and to 
evaluate the patient’s response to exercise associated with 
daily activities. 
Early comprehensive cardiac rehabilitation: 
phase II
Phase II CR may be provided in the inpatient setting (resi-
dential); in the ambulatory setting at an outpatient clinic or 
day rehabilitation unit; as hybrid cardiac telerehabilitation 
with phase I rehabilitation program in the in-hospital or 
ambulatory setting, followed by phase II delivered remotely 
at the patient’s home using data transmission technology.
Inpatient phase II CR should be provided primarily to 
individuals at high cardiovascular risk. This may include pa-
tients:
•	 with complications of ACS, cardiac surgery, or PCI;
•	 with other cardiovascular complications or comorbidi-
ties and high cardiovascular risk with stable advanced 
HF (New York Heart Association [NYHA] functional class 
III–IV) and/or requiring short- or long-term intravenous 
therapy and/or with ventricular assist devices and/or 
other cardiac implantable electronic devices;
•	 immediately after heart transplantation; 
•	 who cannot undergo a CR program at an outpatient 
clinic or a day rehabilitation unit [10].






Following implantation of cardiac implantable electronic devices, pacema-
kers, resynchronization devices, or implantable cardioverter-defibrillators
Following heart valve repair/replacement
Following heart transplantation
Following implantation of ventricular assist devices
Congenital heart disease 
Peripheral artery disease
Following cerebrovascular eventsa
aPatients with paresis or aphasia require neurological rehabilitation
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Late comprehensive cardiac rehabilitation: 
phase III 
Phase III of the CR program is most often delivered in 
the ambulatory setting at an outpatient clinic or a day 
rehabilitation unit. This phase centers on physical exer-
cise and on educating patients and their families about 
a healthy lifestyle, and it should be planned, provided, and 
regularly monitored with consideration of the individual 
patient’s needs, cardiovascular risk profile, and personality 
traits. Phase III should be lifelong as part of the healthy 
lifestyle intervention [13].
At each phase, different models of physical exercises 
(A, B, C, or D) may be prescribed depending on the indi-
vidual patient’s exercise tolerance and cardiovascular risk 
[13]. Model A is applied in patients with the best exercise 
tolerance and the lowest cardiovascular risk, while model 
D, in patients with poor exercise tolerance and high cardio-
vascular risk. Models B and C are used in patients with inter-
mediate levels of exercise tolerance and cardiovascular risk.
Effects of comprehensive cardiac rehabilitation 
All forms of CR provide beneficial health effects. In par-
ticular, CR 
•	 modifies CVD risk factors by increasing physical activity, 
lowering blood pressure (BP), reducing or maintaining 
body weight, improving the lipid profile to achieve 
obtain guideline-recommended targets, controlling 
glucose levels, lowering insulin resistance;
•	 improves endothelial function;
•	 inhibits the development of atherosclerosis and its 
clinical sequelae, and even causes regression of ath-
erosclerotic lesions; 
•	 improves cardiopulmonary efficiency and exercise 
tolerance; 
•	 reduces the risk of frailty syndrome;
•	 improves musculoskeletal function; 
•	 improves psychophysical fitness;
•	 improves the quality of life; 
•	 motivates patients to engage with treatment;
•	 reduces the risk of disability;
•	 improves family and social activity of patients; 
•	 facilitates a return to work.
These benefits are due to the pleiotropic effects of ex-
ercise training, among other factors. When combined with 
patient education and optimal medical therapy, exercise 
training reduces the risk of acute cardiovascular events, 
delays disease progression, and shortens the duration of 
treatment after acute events and exacerbations. This results 
in a lower number of hospital readmissions, improved 
quality of life, and prolonged longevity [14, 15].
EXERCISE TRAINING IN COMPREHENSIVE 
CARDIAC REHABILITATION: ELIGIBILITY 
CRITERIA, CONTRAINDICATIONS, 
AND METHODS 
Determining patient eligibility for comprehensive 
cardiac rehabilitation: general principles 
Exercise training can be prescribed only to clinically stable 
patients. Patients are referred for CR by a physician based 
on medical history, physical examination, and additional 
tests. Medical history should include disease course, comor-
bidities that may affect exercise tolerance and training (e.g., 
diabetes, kidney failure, chronic obstructive pulmonary 
disease, thyroid disease, cancer, chronic inflammatory 
diseases, anemia, as well as musculoskeletal and neurologic 
disorders). Before starting the exercise training program, 
the patient should be assessed for current symptoms 
(NYHA functional classification, Canadian Cardiovascular 
Society classification of angina pectoris, Fontaine and 
Rutherford classification of peripheral artery disease) as 
well as cardiovascular risk (Table 2). 
Patients after cardiac surgery should be assessed for 
the presence of postoperative complications: sternal 
instability, improper wound healing, postoperative infec-
tions, postpericardiotomy syndrome, and postoperative 
anemia. Current medical therapy is also evaluated, and 
modification is considered depending on the clinical sta-
Table 2. Assessment of cardiovascular risk during exercise training [13]
Risk factor Risk
Lowa Moderateb Highb
Left ventricular systolic function No significant dysfunction LVEF 
≥50%
Moderate dysfunction  
LVEF = 36%–49%
Severe dysfunction LVEF ≤35%
Complex ventricular arrhythmia Absent at rest or during exercise Present at rest or during exercise
Ischemic signs on exercise test None ST-segment depression  
≥1 mm–≤2 mm
ST-segment depression >2 mm






Hemodynamic response to exercise Normal Stable or decreased SBP or HR with increased 
workload; peak SBP <140 mm Hg
Clinical characteristics Uncomplicated myocardial 
infarction, CABG, PCI
Myocardial infarction or an invasive intervention 
complicated by shock or cardiac arrest; HF; recur-
rent ischemia after invasive treatment 
aAll criteria met; bOnly 1 criterion met; cThe assessment should include age and sex.
Abbreviations: CABG, coronary artery bypass grafting; HF, heart failure; HR, heart rate; LVEF, left ventricular ejection fraction; MET, metabolic equivalent of task; PCI, percuta-
neous coronary intervention; SBP, systolic blood pressure
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tus and according to general guidelines. When referring 
the patient for physical training, the function of cardiac 
implantable electronic devices should be assessed and 
potential indications for implantation should be considered 
(pacemaker, ICD, cardiac resynchronization therapy, and 
ventricular assist devices).
The patient is examined by a physician before and after 
the CR program. Eligibility is determined on the basis of the 
patient’s general condition, symptoms of HF, heart rate (HR) 
and BP measurement, presence of arrhythmia, peripheral 
vascular disease, as well as musculoskeletal and neurologic 
disorders that limit physical exercise. Medical examination 
should be also performed before each training session in 
patients at high risk of complications, after the training 
program has been modified, or in case of complications. 
Patients are assessed for eligibility and cardiovascular 
risk using the following diagnostic tools:
•	 the ECG — standard ECG should be performed in all 
patients before and after each phase of CR and in the 
presence of symptoms that constitute an indication 
for ECG;
•	 the exercise test — recommended before the patient is 
referred for phase II and III CR. The exercise test is used 
to determine exercise intensity, exercise-related risk, as 
well as changes in exercise capacity after completing 
each phase of CR. It is also applied to determine work-
load for subsequent physical activity associated with 
work and leisure [16];
•	 the cardiopulmonary exercise test (CPET) — is recom-
mended for functional assessment and rehabilitation of 
patients with CVD (particularly HF) as well as heart and 
lung transplant recipients. The CPET allows a precise 
assessment of exercise capacity by measuring minute 
ventilation as well as oxygen and carbon dioxide con-
centrations in exhaled air during the test [17];
•	 the 6-minute walk test [18] — is used in patients who 
cannot do the exercise test either on a treadmill or bi-
cycle ergometer [11]. However, the treadmill stress or 
bicycle ergometry test should be always performedas 
soon as possible if there are no contraindications; 
•	 long-term ambulatory Holter ECG monitoring — should 
be performed in patients who develop symptoms that 
constitute an indication for this type of ECG moni-
toring [19];
•	 transthoracic echocardiography — if current results 
after a recent cardiovascular event are not available, 
transthoracic echocardiography should be performed 
at a center providing a phase II CR program. Standard 
anatomical and functional parameters should be 
assessed. Before referral for exercise-based CR, it is 
important to assess the pericardium and to exclude 
mobile thrombi in heart cavities. Mobile thrombi con-
stitute an absolute contraindication to exercise training. 
Transthoracic echocardiography is used in risk stratifica-
tion of patients undergoing exercise training (Table 2). 
Moreover, echocardiography should be performed in 
patients with disease exacerbation or other indications 
as defined by the guidelines of European Society of 
Cardiology and the Polish Society of Cardiology [20, 21]; 
•	 laboratory tests — the following laboratory tests 
should be performed before the patient is referred for 
CR: complete blood count, lipid profile (total choles-
terol, high- and low-density lipoprotein cholesterol, 
and triglycerides), fasting glucose, glycated hemo-
globin HbA1c in patients with diabetes, creatinine, 
electrolytes, uric acid, and international normalized 
ratio (in patients receiving vitamin K antagonists). 
The frequency of laboratory testing should follow the 
established guidelines.
Exercise training in comprehensive cardiac 
rehabilitation: basic concepts, contraindications, 
and methods 
Exercise training in CR is a key treatment of patients with 
CVD and is prescribed at each phase of CR. 
•	 Phase I: exercise training is started as soon as the patient 
with an emergency medical condition is stabilized or 
after an elective procedure. Depending on the disease 
course (complicated vs uncomplicated) and in the ab-
sence of contraindications, active rehabilitation starts 
after 12 to 48 hours of immobilization in patients with 
a stable clinical condition. Subsequent components 
of the training program are implemented depending 
on the disease course and complications during the 
acute phase. 
•	 Phase II: exercise training depends on exercise capacity 
and the risk of complications as the most important 
criteria to be considered when referring the patient for 
one of the 4 models of physical exercise (A, B, C, or D). 
The training can be performed in the in-hospital setting, 
ambulatory setting (outpatient clinic/day rehabilitation 
unit), or as part of hybrid cardiac telerehabilitation. 
•	 Phase III: exercise training is delivered as part of late CR 
in the ambulatory setting. The goal of exercise train-
ing is to further improve exercise tolerance, maintain 
treatment outcomes, and reduce the risk of disease 
recurrence. Exercise training at this stage should be 
lifelong. 
To increase patient safety during training, a number of 
measures should be undertaken. Before training, the patient’s 
clinical condition should be assessed, while during training, 
the patient should be monitored for sudden paleness, ex-
cessive sweating, blue lips, and other symptoms. Patients 
should be educated about any exercise-related symptoms 
such as chest pain, dyspnea, and dizziness as well as the need 
to report them to the rehabilitation team. Before and after 
an exercise training session as well as on each change of the 
body position, BP and HR should be measured. Knowledge 
of first-aid principles also increases patient safety.
Any emergency medical condition and unstable CVD 
constitute absolute contraindications to exercise training. 
An exercise training program should be tailored to the 
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individual patient’s needs or temporarily discontinued 
(especially phases I and II) in the following conditions: 
•	 poorly controlled hypertension; 
•	 orthostatic BP reduction of more than 20 mm Hg with 
clinical symptoms; 
•	 sinus tachycardia resistant to treatment (HR >100 bpm); 
•	 malignant ventricular tachycardia; 
•	 exercise-induced bradycardia; 
•	 significant stenosis of the atrioventricular or arterial 
ostium; 
•	 cardiomyopathy with left ventricular outflow tract 
stenosis; 
•	 ischemic ST-segment depression of 2 mm or higher 
on resting ECG; 
•	 a positive exercise test result suggesting myocardial 
ischemia at peak exercise;
•	 decompensated HF; 
•	 acute inflammation and uncontrolled comorbidities;
•	 electrolyte imbalance [13, 22].
The intensity and duration of training should be tailored 
to each individual patient. In patients with CVD, the standard 
form of training is endurance aerobic exercise that involves 
large muscle groups. An interval or a continuous modality 
of training can be applied. Resistance/strength exercise is 
also recommended, starting with phase II of CR, after at 
least 1 week of supervised endurance exercise training [23].
Exercise training should adopt the FITT principle (fre-
quency, intensity, time–duration, and type of exercise), 
with additional consideration of the timing in relation to 
meals (FITT+T). 
Exercise training should be arranged to provide an 
energy consumption of 1000 to 2000 kcal/week [11].
•	 Frequency of exercise training
For aerobic training, at least 3 days a week, preferably 
all days per week; 
for resistance/strength training, 2 times a week on 
nonconsecutive days of the week.
•	 Intensity of exercise 
Endurance training
Moderate intensity: for endurance interval training: 
45%–59% of peak oxygen consumption (VO2peak), 
50%–70% of peak exercise capacity above the first 
ventilatory threshold (Wpeak), 55%–69% of peak HR, 
40%–59% of HR reserve, 4–6 metabolic equivalents 
or a score of 12 to 14 on the 6–20 Borg rating of per-
ceived exertion scale, or moderate-to-high intensity for 
continuous endurance training. High-intensity interval 
training is also allowed. The “speech rule” can be used 
as an additional tool to monitor training intensity when 
HR measurement is not possible. 
Resistance/strength training 
Intensity from 30% to 70% of 1-repetition maximum 
(1RM) for the upper body and 40% to 80% 1RM for the 
lower body, with 12 to 15 repetitions in one set.
•	 Duration of training sessions
At least 20 to 30 minutes (preferably 45–60 minutes) 
per session.
•	 Type of training 
Aerobic training (walking, jogging, cycling, swimming, 
rowing, dancing), resistance/strength training, flexibil-
ity, balance, and inspiratory muscle training. Noncon-
ventional types of training are also allowed.
During the initial phases, supervised exercise training 
is recommended, with a physical examination as well as 
HR and BP monitoring before, during, and after training. 
Supervision should be prolonged in patients with new 
symptoms, BP abnormalities, or exacerbation of arrhythmia 
during exercise [11].
HYBRID CARDIAC TELEREHABILITATION
Hybrid cardiac telerehabilitation offers an opportunity to 
provide and supervise a rehabilitation program remotely 
by using advanced medical and telecommunication tech-
nology [24–30]. 
Hybrid cardiac telerehabilitation has been approved 
for use by the Polish Cardiac Society [31, 32]. The setting, 
duration, and components of phase I hybrid cardiac reha-
bilitation are presented in Table 3. Phase II rehabilitation is 
delivered at the patient’s home. It comprises 15 to 20 train-
ing sessions 3 to 5 times a week and a follow-up visit for 
clinical assessment, outcome evaluation, and advice on 
treatment and lifestyle modification. The core components 
of a training session in hybrid cardiac telerehabilitation are 
presented in Table 4. 
Exercise training in hybrid cardiac 
telerehabilitation 
Exercise training in hybrid cardiac telerehabilitation should 
be tailored to the individual patient according to current 
guidelines. The type of home-based exercise training 
depends on the availability of at-home physical therapy 
equipment. If physical therapy equipment is not available 
to the patient, outdoor walking is recommended.
Telerehabilitation system
A telerehabilitation system should ensure voice communi-
cation, recording and transmission of ECG parameters, BP, 
and body mass, as well as remote training control.
Monitoring unit 
The monitoring unit should be equipped with a comput-
er-based system enabling assessments listed in Table 4 and 
ensuring communication with the patient in case of alarm-
ing symptoms. 
In Poland, hybrid cardiac telerehabilitation services may 
be provided in daily clinical practice [33], both as a sepa-
rate procedure or as part of coordinated specialty care for 
patients after myocardial infarction [34].
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MAJOR CLINICAL INDICATIONS FOR 
CARDIAC REHABILITATION AND PROVISION 
OF REHABILITATION SERVICES
Coronary artery disease
Comprehensive CR is a mainstay of secondary prevention 
of coronary artery disease (CAD). It is recommended by 
the European Society of Cardiology (ESC) guidelines and 
other international societies (class IA recommendation) to 
improve prognosis in patients with ACS, after revasculari-
zation (coronary angioplasty, PCI, coronary artery bypass 
grafting [CABG]), and with CCS.
Phase II CR should start no longer than 3 months after 
a cardiovascular event. The recommended frequency of 
supervised training sessions is at least 3 to 5 times per 
week, with intensity tailored to the patient’s individual 
clinical condition. At the same time, CR should include 
atherosclerotic risk factor modification and patient edu-
cation about CAD.
Patients after acute coronary syndrome 
Cardiac rehabilitation is an effective intervention in pa-
tients after ACS (class IA recommendation according to 
the ESC guidelines). Comprehensive CR reduces cardio-
vascular mortality and the risk of recurrent myocardial 
infarction [35]. Effective CR requires a comprehensive 
approach [15].
Direct outcomes of CR in patients after ACS include 
improved exercise capacity, modification of atherosclerotic 
risk factors, improved mental health, and better adherence 
to medical therapy. 
Comprehensive CR in patients after ACS includes all 
3 phases described earlier (see chapter: Comprehensive 
cardiac rehabilitation: definition, goals, target population, 
and organization of rehabilitation services). For the CR 
program to be effective, it has to be started no later than 
3 months after hospital discharge [15]. 
Depending on the clinical condition and complications, 
phase II CR in these patients is most often provided in 
the ambulatory setting in a day rehabilitation unit or as 
hybrid cardiac telerehabilitation. In-hospital phase II CR is 
recommended only in patients with high cardiovascular 
risk, complications of ACS, HF (NYHA functional class III 
and IV), numerous comorbidities, or in those who cannot 
participate in other forms of rehabilitation due to logistical 
reasons and/or age. Irrespective of the setting, CR should 
be delivered using a comprehensive approach (Table 5) 
by a team of professionals (see chapter: Comprehensive 
cardiac rehabilitation: definition, goals, target population, 
and organization of rehabilitation services).
After completing phase II CR, patients after ACS are 
referred for outpatient care with recommendations to 
maintain a healthy lifestyle, including daily physical activity.
Chronic coronary syndrome 
Comprehensive CR is recommended by the ESC guide-
lines in the treatment of patients with CCS (class IA recom-
mendation). Indications for CR in patients with CCS include:
•	 stable CAD without a history of myocardial infarction 
and revascularization (angina symptoms or exertion 
dyspnea with confirmed coronary artery atherosclerosis 
without the possibility of revascularization); 
•	 stable CAD long after myocardial infarction and revas-
cularization (phase III CR);
•	 angina and suspected vasospastic or microvascu-
lar disease.
Comprehensive CR in patients with CSC (Table 6) 
facilitates implementation and maintenance of a healthy 
lifestyle as well as elimination of atherosclerotic risk 
factors, which limits the progression of atherosclerotic 
lesions. Comprehensive CR improves exercise tolerance, 
Table 3. Phase I hybrid cardiac telerehabilitation: setting, duration, 
and components
Setting: in-hospital (cardiac rehabilitation ward); ambulatory (day rehabili-
tation unit/outpatient clinic)
Duration: optimally 5 days; up to 14 days in patients with comorbidities, 
depending on the clinical status
Scope:
1.  Clinical assessment and optimization of pharmacotherapy (physical 
examination, additional tests including laboratory tests, ECG, echocar-
diography, and others if indicated)
2.  Exercise capacity assessment (exercise test, CPET, or 6-minute walk test)
3.  Tailored exercise training program in terms of:
 — duration and frequency of training sessions
 — exercise intensity (training HR zone, Borg rating of perceived exertion)
 — type of exercise training (endurance training, respiratory muscle tra-
ining, resistance/strength, whole-body training including stretching)
— training modality (continuous, interval)
— extent of physical exercise (general, local)
4.  Programming of the telerehabilitation system that includes: 
 — exercise training program
 — rules, parameter recording and transmission schedule (ECG, BP, body 
mass)
5.  mental health assessment and development of tailored psychological 
support program
6.  education on the use of the telerehabilitation system, self-assessment 
during telerehabilitation, implementation of exercise training, healthy 
lifestyle, and CVD prevention
7.  gradual implementation of the exercise training program: first supervi-
sed training sessions
8.  evaluation of the patient’s ability to use the telerehabilitation system 
and readiness for home-based CR
9.  final referral of the patient for home-based CR
10. first aid training for patients and their partners/children
Abbreviations: BP, blood pressure; CPET, cardiopulmonary exercise test; CR, cardiac 
rehabilitation; CVD, cardiovascular disease; ECG, electrocardiogram; HR, heart rate 
Table 4. Core components of a training session in hybrid cardiac 
rehabilitation
The core components of a training session include:
1.  Permission to start a training session based on: 
— medical interview by phone
— ECG, HR, and body mass measurement
— assessment for contraindications to exercise training (see chapter: Exer-
cise training in comprehensive cardiac rehabilitation: basic concepts, 
contraindications, and methods)
2.  Exercise training guided by the telerehabilitation system with a pro-
grammed recording and transmission of ECG parameters
3. Summary of the training session including: 
— a medical interview
— training evaluation: ECG (including training HR), perceived exertion 
according to the Borg scale, adverse events
— advice on the next training session
Abbreviations: ECG, electrocardiogram; HR, heart rate
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Table 5. Components of comprehensive cardiac rehabilitation following acute coronary syndrome and percutaneous coronary intervention [11]
Components of 
comprehensive CR
Assessed parameters / measures 
Medical interview, 
physical examina-
tion, and additional 
tests
— Clinical history: clinical course of ACS, comorbidities, evaluation of atherosclerotic risk factors
— Current symptoms (NYHA class, Canadian Cardiovascular Society angina class, Fontaine and Rutherford classification for lower 
extremity peripheral artery disease)
— Review lifestyle modifications (diet, smoking, weight control, BP self-monitoring, glucose control, subjective assessment of exercise 
tolerance and extracardiac symptoms)
— Physical activity level: domestic, occupational, and recreation; barriers to increased physical activity
— Physical examination: heart failure symptoms, arrhythmia, HR and BP control, extracardiac atherosclerotic manifestations, frailty 
syndrome, musculoskeletal disorders, and neurologic symptoms 
— Resting ECG
— Echocardiography (systolic and diastolic dysfunction and other abnormalities if present). In patients with LVEF <40%, repeat 
echocardiography 6–12 weeks after myocardial infarction, complete revascularization, and optimal medical therapy to determine 
indications for primary prevention ICD implantation of sudden cardiac death
— Peak exercise capacity evaluation before CR and after CR completion (exercise test, preferably CPET). If the exercise test is not 
feasible, perform the 6-MWT
— Consider assessment of myocardial ischemia and left ventricular myocardial viability if indicated (stress echocardiography, magne-
tic resonance imaging, single-photon emission computed tomography, or positron emission tomography, if not performed during 
acute hospitalization) 
Physical activity During CR:
— supervised prescribed aerobic exercise training with workload determined on the basis of exercise capacity and the risk of compli-
cations
— resistance/strength training to improve exercise capacity and muscle strength
Recommendations on physical activity levels in everyday life:
— at least 30 min/day, 5 days a week of moderate-intensity physical activity (150 min/week), or 15 min/day, 5 days a week of vigoro-
us-intensity physical activity (75 min/week), or a combination of both. In patients who cannot do exercise for 10 minutes, shorter 
sessions (i.e., <10 min) are appropriate
Patient counseling — Expected outcome of CR
— Atherosclerotic risk factors and their modification
— Causes and course of the disease
— Self-assessment of symptoms
— Medical therapy 
— Diet
— Physical activity, return to sexual activity
— Return to work
Psychological 
evaluation
— Work and daily stress
— Social support, social isolation
— Depression, anxiety
— Cognitive function assessment
— Selection of patients with indications for psychotherapy and/or psychiatric treatment
Abbreviations: 6-MWT, 6-minute walk test; ACS, acute coronary syndrome; BP, blood pressure; CPET, cardiopulmonary exercise test; CR, cardiac rehabilitation; ECG, electrocar-
diogram; HR, heart rate; ICD, implantable cardioverter-defibrillator LVEF, left ventricular ejection fraction; NYHA, New York Heart Association
Table 6. Components of comprehensive cardiac rehabilitation in patients with chronic coronary syndrome [11]
Components of CR Assessed parameters/measures
Medical interview and 
physical examination
— Review clinical history of disease, consider cardiovascular events, comorbidities, and imaging studies (echocardiography, 
coronary angiography)
— Evaluate atherosclerotic risk factors and consider modification
— Subjective assessment of exercise tolerance
— Assess physical activity levels: domestic and recreational
— Review medical therapy of coronary artery disease and comorbidities (modification of pharmacotherapy based on general 
guidelines, if indicated)
— Psychological evaluation
— Evaluation of social conditions
— Physical examination with assessment of extracardiac atherosclerotic manifestations
Additional tests — Resting ECG
— Symptom-limited exercise test at baseline and after completion of the CR program 
— In selected cases, echocardiography and long-term ECG Holter monitoring based on general guidelines)
Exercise training — ECG and BP monitoring; duration of monitoring determined by the physician
— Combined aerobic and resistance/strength training
— 30–60 min/day sessions, at least 3–5 days a week
— Exercise intensity (see chapter: Exercise training in comprehensive cardiac rehabilitation: basic concepts, contraindications, 
and methods)
Abbreviations: BP, blood pressure; CR, cardiac rehabilitation; ECG electrocardiogram
exercise capacity, and the quality of life of patients. More-
over, it reduces all-cause and cardiovascular mortality as 
well as rehospitalization rates [15, 36]. 
Heart failure
Rehabilitation in the treatment of patients with HF is 
recommended by several current guidelines [7, 37–39]. 
A tailored exercise program should be started as soon as 
the patient is clinically stable. The program starts with 
gradual mild mobilization including respiratory muscle 
and small muscle group exercise as an introduction to 
regular training sessions [4, 39]. Contraindications to 
exercise training and exercise-related risk factors are 
described in Chapter 2. 
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Baseline studies
Prior to starting a CR program, a medical interview and 
physical examination should be performed. Additionally, 
patients should undergo laboratory tests, 12-lead resting 
ECG, exercise test, and, if indicated, chest computed to-
mography, echocardiography, and long-term ECG Holter 
monitoring. 
Developing an exercise training plan 
An exercise training program is planned on the basis of 
functional assessment. The CPET is recommended as the 
gold standard, but, if unavailable, the standard exercise 
test or the 6-minute walk test should be performed. The 
patient’s age, previous lifestyle, and individual preferenc-
es should be considered. An individualized training plan 
should also include exercise tolerance determined by the 
Borg rating of perceived exertion scale (moderate exertion 
is recommended: 10–14 on the 6–20 Borg scale). 
A training session should include endurance, respira-
tory, and resistance/strength exercise with elements of 
stretching. 
Endurance training 
The most popular and accessible types of endurance train-
ing for patients with HF are cycle ergometer training, walk-
ing (on a treadmill or outdoor), and Nordic walking. Con-
tinuous endurance or interval training can be prescribed. 
Continuous endurance training 
In patients with significant impairment of exercise capacity, 
baseline low-intensity training of 5 to 10 minutes is recom-
mended, gradually increased to 30, 45, and 60 minutes. The 
frequency is 3 to 5 times/week, with gradually increasing in-
tensity. Exercise training should start at a level of 40% to 50% 
of VO2peak, then gradually increase to 70% to 80% of VO2peak or 
VO2 reserve (i.e., a difference between resting VO2 and VO2pe-
ak). If CPET is unavailable, the training HR zone is determined 
on the basis of the exercise test. The recommended range 
is 40% to 70% of the HR reserve (i.e., a difference between 
resting and peak HR during the exercise test) [39]. 
Interval endurance training 
Moderate to high-intensity exercises (10 sec–4 min) 
(50%–100% of peak exercise capacity) are interrupted 
by low-intensity or recovery intervals (1–3 min). A single 
training session usually consists of 4 sets of high-intensity 
and recovery intervals, as described above, preceded by a 5- 
to 10-minute warm-up and followed by a 5- to 10-minute 
cool-down [39]. 
Inspiratory muscle training
Inspiratory muscle training starts at an intensity of 30% of 
maximal inspiratory pressure, gradually increased (every 
7–10 days) to achieve a maximal inspiratory pressure of 
60%. Training duration should be 20 to 30 min/day, with 
a frequency of 3 to 5 sessions a week [39], This type of 
training can be performed using, for example, a Threshold 
Inspiratory Muscle Trainer. In addition, exercises targeting 
the breathing type and rate, as well as diaphragmatic 
breathing training, are appropriate.
Resistance/strength training and stretching 
Impaired skeletal muscle function is one of the causes of 
poor exercise tolerance in patients with HF. A CR program 
that includes resistance/strength and stretching training 
prevents muscle atrophy and weakness, thus reducing 
disease-related cachexia. Training intensity is expressed 
as a percent of 1RM, defined as the maximum amount of 
weight that a person can possibly lift for 1 repetition. It is 
important to determine the time relationship between 
muscle contraction (1–3 s) and relaxation (e.g., a ratio of 1:2). 
Training intensity should start at 30% 1RM, 5 to 10 rep-
etitions, 2 to 3 sessions a week, 1 to 3 sets per session. 
Then, the intensity is gradually increased to 30% to 40% 
1RM, 12 to 25 repetitions, 2 to 3 sessions a week, 1 set per 
session. In patients with good exercise tolerance, training 
intensity can be increased to 40% to 60% 1RM, 8 to 15 rep-
etitions, 2 to 3 sessions a week with 1 set per session [39]. 
The development of an exercise training plan for patients 
with HF depending on exercise capacity, age, and lifestyle 
is presented in Table 7 [39].
Table 7. Development of an exercise training plan for patients with heart failure depending on exercise capacity, age, and lifestyle [39]
Exercise capacity Age and physical activity
Age <65 years Age ≥65 years
Active lifestyle Predominantly  
sedentary lifestyle
Active lifestyle Predominantly  
sedentary lifestyle 
VO2peak ≤10 ml/kg/min












VO2peak >10 ml ≤18 ml/kg/min


























Abbreviations: 6-MWT, 6-minute walk test; CT, continuous training; HIIT, high-intensity interval training; IT, interval training; LIIT, low-intensity interval training; RMT, respirato-
ry muscle training; RST, resistance/strength training;VO2peak, peak oxygen consumption on cardiopulmonary exercise test
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The training program starts with shorter sessions 
with the aim to achieve at least the lower exercise train-
ing intensity. Then, the duration of training sessions 
and intensity are gradually increased until the upper 
exercise training intensity is achieved, depending on the 
patient’s capabilities.
Patients with heart failure and a pacemaker, 
cardiac resynchronization therapy and/or 
implantable cardioverter-defibrillator, as well as 
left ventricular or biventricular assist device
Implantable cardioverter-defibrillator
A large percentage of patients with HF with reduced left 
ventricular ejection fraction undergo ICD and/or CRT im-
plantation. In most patients, particularly those with CRT 
[7, 39, 40], rehabilitation significantly improves exercise 
tolerance. The exercise test (preferably CPET) is used to 
assess features of myocardial ischemia (except after CRT 
implantation), exercise tolerance, chronotropic response, 
arrhythmia, and HR control with medical therapy, including 
the risk of reaching antitachycardia pacing (ATP) and shock 
thresholds [7, 39, 40].
The training program should be set to maintain a max-
imum HR at a level of 20 bpm below the defibrillation 
threshold. The rehabilitation team should be trained on 
the management of ICD interventions [7, 39, 40].
Data that should be collected by the rehabilitation team 
to develop an exercise training program for patients with 
ICD are summarized in Table 8.
In most patients, exercise training can be started 
6 weeks after implantation. This refers particularly to exer-
cises for the shoulder girdle on the implantation side. It is 
generally agreed that electrode position is fully stabilized 
within up to 6 weeks after implantation. Prior to that, mild 
exercises for mobilization of the upper extremity on the im-
plantation side can be performed to avoid frozen shoulder.
Any ICD intervention during CR should prompt a con-
sultation with an electrophysiologist. Temporary discon-
tinuation of CR should also be considered (especially if 
hemodynamic abnormalities are present, such as electrical 
storm). After ICD adjustment, patient response to exercise 
should be assessed. Rehabilitation can be continued if 
the patient’s condition is stable and arrhythmia control is 
achieved [7, 39, 40].
Cardiac resynchronization therapy
Apart from general indications, the exercise test in patients 
with CRT pacemaker and CRT defibrillator (CRT-D) is used 
primarily to assess chronotropic response and stimulation 
outcome [39, 40]. 
Data that should be obtained to develop a CR pro-
gram in patients with CRT or CRT-D are the same as for 
patients with ICD (as summarized in Table 8). Additionally, 
information on the upper tracking rate, upper sensor rate, 
and rate responsiveness (acceleration of stimulated heart 
rhythm response to exercise in patients with chronotropic 
incompetence) should be collected [7, 39, 40].
The exercise training program for patients with CRT, 
CRT-D, or CRT pacemaker is developed in the same way as 
for patients with HF and ICD. The CR team should be trained 
on the management of device-related events because 
the loss of resynchronization stimulation or an increase 
in HR above the upper sensor rate may result in a sudden 
decrease in cardiac output. This requires immediate dis-
continuation of the training session and CRT adjustment 
[7, 39, 40].
Left ventricular or biventricular assist devices
Available studies confirmed the beneficial effects of CR 
in patients with long-term mechanical circulatory support 
[41, 42]. Apart from the components of CR, patients are 
instructed on how to use the device, how to approach 
fluctuations in international normalized ratio, and how to 
take care of the driveline exit site. Patients with long-term 
mechanical circulatory support should undergo CR at an 
experienced center [41, 42]. Training intensity during phase 
II of CR should be determined on the basis of the Borg scale 
and exercise test results (preferably CPET or 6-minute walk 
test). Resistance/strength training is also recommended, 
particularly of the lower extremity muscles. Walking 
is a valuable complementary type of training [41, 42]. 
Jogging, rowing, crossfit, abdominal exercises, overhead 
shoulder exercises (such as weightlifting), and swimming 
are not recommended.
Apart from general contraindications to exercise-based 
CR [41, 42], exercise training in patients with ventricular 
assist devices should not be prescribed in the case of 
device complications during or after the training session 
(e.g., alarm activation, complex and frequent ventricular 
tachycardia, infection [particularly at the driveline exit 
site], bleeding symptoms, thrombotic complications) and 
ICD intervention.
Despite cardiac unloading, patients with a ventricular 
assist device have significantly lower exercise capacity, with 
VO2peak lower than 50% of the normal value. 
Table 8. Data required to develop an exercise training program for 
patients with implantable cardioverter-defibrillator [7, 39, 40] 
Patient-related data: 
— Indications for ICD implantation (primary, secondary prevention) 
— Previous arrhythmia (ventricular, supraventricular tachycardia), ICD 
interventions
— Effect of previous arrhythmia on the hemodynamic status 
— Triggers of arrhythmia (e.g., myocardial ischemia) 
— Medication use (e.g., antiarrhythmic drugs)
— NYHA functional class
Device-related data:
— Arrhythmia detection threshold (ventricular tachycardia/fibrillation 
zone: HR in the ICD intervention zone)
— Type of antiarrhythmic ICD intervention protocol — stimulation and 
defibrillation sequence
Abbreviations: HR, heart rate; ICD, implantable cardioverter-defibrillator; NYHA, 
New York Heart Association
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Pacemaker
In line with the general principles, the training pro-
gram should be developed on the basis of exercise test 
results. Among other parameters, the exercise test allows an 
assessment of chronotropic response to exercise. Patients 
with chronotropic incompetence and rate-responsive pace-
maker to increase HR during exercise constitute a specific 
population. In patients with normal left ventricular ejection 
fraction (≥55%), the optimum upper pacing rate limit was 
reported to reach 86% of age-predicted maximum HR, and 
in patients with reduced left ventricular ejection fraction 
(≤45%), it was 75% [43].
Patients after cardiac surgery 
Comprehensive CR should be an integral component of 
the management of patients after cardiac surgery, includ-
ing CABG, heart valve surgery, and heart transplantation. 
Participation in a rehabilitation program after CABG was 
associated with a 40% reduction in mortality [15].
Comprehensive CR in patients after cardiac 
surgery 
Phase I CR is provided in the inpatient setting. It starts on 
the day of surgery at the intensive care unit and is then 
continued in a postoperative recovery room.
Rehabilitation includes:
•	 respiratory muscle exercises that should be started 
immediately after extubation;
•	 antithrombotic prophylaxis, arm and leg exercises, 




•	 gradual mobilization of the patient.
Phase II CR is provided in the inpatient setting (resi-
dential), as an outpatient service, or as hybrid cardiac tel-
erehabilitation.
In the initial phase after the surgery, exercise capacity 
can be assessed using the 6-minute walk test. The symp-
tom-limited exercise test should be performed as soon as 
possible [3].
Patients may develop postoperative complications that 
may require modifications in the CR program.
Comprehensive CR after cardiac surgery should incor-
porate:
•	 respiratory muscle exercises;
•	 antithrombotic prophylaxis, upper and lower extremity 
exercises (particularly those targeting the lower extrem-




•	 optimal treatment of comorbidities;
•	 diagnosis and prevention of malnutrition;
•	 psychological support, especially in patients with sleep 
disorders, anxiety, depression, poor mental health, and 
reduced quality of life;
•	 postoperative follow-up (echocardiography, imaging 
studies, long-term Holter ECG monitoring) to identify 
complications and modify the rehabilitation program.
Comprehensive cardiac rehabilitation following 
coronary artery bypass grafting
In experienced centers, phase II CR can be started imme-
diately after discharge from surgery facilities. Exercise 
training that may adversely affect sternal closure should 
be avoided [44].
In patients after CABG, the type and scope of exercise 
should be determined on the basis of the surgical access: 
standard sternotomy vs minimally invasive or lateral approach. 
Some patients after sternotomy may benefit from the 
use of sternum support vests [45]. Upper body stretching 
exercises can be started 6 weeks after the surgery. Patients 
should sleep on the back for 2 to 3 months until sternal 
stability is achieved.
Comprehensive cardiac rehabilitation in patients 
undergoing heart valve surgery
Comprehensive CR following heart valve surgery using 
either a surgical or percutaneous method may improve 
exercise tolerance, functional independence, maximum 
exercise capacity, and quality of life [46, 47].
Patients after heart valve surgery require much more 
time to improve exercise tolerance compared with those 
after CABG. Exercise tolerance is considerably lower after 
mitral vs aortic valve replacement, especially in patients 
with pulmonary hypertension [48]. Recommendations on 
protection of the sternum after heart valve surgery with 
sternotomy are the same as for patients after CABG.
Patients after transcatheter aortic valve implantation 
(TAVI) should initially undergo a center-based CR program, 
which may be continued in the outpatient and home-based 
settings [11].
Comprehensive cardiac rehabilitation in patients 
undergoing heart transplantation
Patients after heart transplantation have a number of spe-
cific features that should be considered in CR, such as those 
resulting from heart denervation, including accelerated 
resting HR, chronotropic incompetence (i.e., inadequate 
acceleration of HR in response to exercise, delayed return 
to resting HR), elevated resting BP, peripheral effects of 
long-term HF (i.e., skeletal muscle atrophy and metabolic 
abnormalities, osteoporosis, reduced skeletal muscle 
strength, chemoreceptor and ergoreceptor hypersensitiv-
ity), side effects of immunosuppressive and corticosteroid 
treatment, increased risk of infection, and risk of acute and 
chronic graft rejection [49].
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Differences in the CR program in this patient population 
are listed below.
•	 For testing protocols, small increments of 10 W/min 
on a bicycle ergometer, or ramp protocols, modified 
Bruce protocols, or Naughton protocols on a treadmill 
are appropriate.
•	 Exercise intensity should be determined based on the 
Borg rating of perceived exertion scale. The recom-
mended intensity is 12 to 14 on the 6–20 Borg scale [11].
•	 Aerobic training should start at low intensity (<50% 
VO2 peak or 10% below the anaerobic threshold) or peak 
workload (<50%) and gradually increase. 
•	 The CR program should incorporate resistance/strength 
exercises, which increase muscle mass and bone den-
sity and prevent adverse effects of immune therapy. 
•	 Hemodynamically stable patients should undergo CPET 
to guide detailed exercise recommendations.
Comprehensive CR was shown to be effective in revers-
ing the pathophysiological effects of heart denervation 
and skeletal muscle atrophy as well as improving exercise 
capacity in this population of patients [50].
PSYCHOSOCIAL RISK FACTORS INFLUENCING 
THE COURSE OF CARDIAC REHABILITATION
Psychological and social factors may affect the treatment 
course and outcomes [4, 51, 52]. Before starting a CR pro-
gram, a psychological evaluation should be performed with 
the assessment of the patient’s psychosocial well-being and 
quality of life, psychopathological symptoms, lifestyle-re-
lated risk factors, attitude to the disease, and any current 
psychosocial problems.
The aim of clinical psychological evaluation is to identify 
risk factors as well as psychological resources of the patient 
in order to develop a management plan in cooperation with 
the patient and to determine a therapeutic intervention 
[53, 54]. A psychological interview and observation are the 
most important clinical tools for psychological assessment. 
To obtain clinical data, psychological questionnaires are 
recommended [55–65].
As part of psychological management, patients should 
be provided with individual or group counseling consistent 
with the goals of CVD prevention. The main areas of psy-
chological education are the physiology of stress, methods 
to reduce emotional tension and develop coping skills, the 
effect of personality traits and lifestyle on treatment, the 
effect of depression/anxiety on somatic health, motivation 
to undergo treatment, and the role of social support. A CR 
program should also include behavioral counseling and 
relaxation techniques training (e.g., progressive muscle 
relaxation, guided visualizations, meditation and mindful-
ness, autogenic training).
Psychosocial risk factors in patients undergoing CR 
include adjustment disorders or psychopathological symp-
toms (depression/anxiety/high level of hostility) and lack of 
social support [66, 67]. Patients with adjustment disorders 
should receive psychological counseling and their relatives 
should be actively involved in the therapeutic process. In 
patients with the diagnosis of mental disorders (e.g., de-
pression, anxiety disorder), medical therapy supported by 
psychotherapy should be used.
Psychological interventions are beneficial not only by 
improving treatment acceptance and the quality of life but 
also by reducing stress, depression, anxiety, and mortality 
of patients with CVD [4, 51–56]. The cognitive-behavioral 
approach has been shown to be the most effective in CR, 
but the choice of a psychological intervention should be 
tailored to the individual patient’s needs and capabilities 
[68, 69].
SECONDARY PREVENTION OF 
CARDIOVASCULAR DISEASE IN PATIENTS 
UNDERGOING CARDIAC REHABILITATION
Secondary prevention should be one of the most important 
tasks in CR. It is achieved by health education, motivation 
to lifestyle changes, and modification of medical therapy 
[4, 11, 70].
Lipid disorders
The secondary prevention targets in all patients at very high 
cardiovascular risk are low-density lipoprotein cholesterol 
levels of less than 55 mg/dl and at least 50% reduction from 
baseline [11, 71, 72] A reduction in low-density lipoprotein 
cholesterol levels below 40 mg/dl is recommended in 
patients after a subsequent cardiovascular event. Statins 
are the drug of choice [71–73]. If treatment goals are not 
reached at the highest tolerated statin dose, the addition 
of a selective cholesterol absorption inhibitor, ezetimibe, is 
recommended, followed by a PCSK9 inhibitor (evolocumab, 
alirocumab). These drugs are also recommended in patients 
with statin intolerance [71, 72, 74–76].
If the patient reports skeletal muscle pain, it is important 
to differentiate the etiology between either the effect of 
training or the adverse effect of hypolipidemic treatment.
Lifestyle modification is recommended to support the 
treatment of lipid disorders.
Obesity and overweight
In all patients, reduction of excessive weight or mainte-
nance of normal weight is recommended. Both overweight 
and obesity are associated with an increased risk of cardio-
vascular and all-cause mortality. The lowest all-cause mor-
tality rates are reported in patients with a body mass index 
of 20 to 25 kg/m2 (aged <60 years). Normal body weight in 
elderly people is higher than in young and middle-aged 
individuals [77]. In all patients with obesity and overweight, 
a healthy diet is recommended along with maintenance or 
reduction of energy intake to achieve a body mass index 
of 20 to 25 kg/m2 and a waist circumference of 94 cm or 
lower in men and of 80 cm or lower in women [78]. As an 
adjunctive treatment, medical therapy (orlistat) or bariatric 
surgery can be appropriate [79]. Incretin therapy, originally 
used in patients with diabetes (glucagon-like peptide-1 re-
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ceptor agonists), seems to be a promising approach in the 
treatment of obesity [80, 81].
Hypertension
In all patients, normal BP values should be maintained [82]. 
Most patients require the use of combination antihyper-
tensive drugs. The choice of medication depends on the 
presence of comorbidities, among other factors. 
Diabetes
The treatment of patients with diabetes is multifactorial 
and includes monitoring of glucose levels, lipid disorders, 
BP, and body mass. Although intensive treatment of high 
blood glucose levels reduces the risk of vascular complica-
tions, it is important to avoid episodes of hypoglycemia, es-
pecially in elderly patients. In all patients with diabetes and 
high blood glucose levels, secondary prevention should 
involve statin treatment with a reduction of low-density 
lipoprotein levels to reach the same targets as in very high-
risk patients. Patients with type 2 diabetes and cardiovas-
cular comorbidities were shown to benefit from treatment 
with canagliflozin [83, 84] and incretin drugs (glucagon-like 
peptide-1 receptor agonists) [85–87]. Intensive treatment 
of hyperglycemia reduces the risk of microvascular compli-
cations. The target glycated hemoglobin HbA1c is less than 
7%, with more stringent targets in young patients (≤6.5%) 
and less stringent targets in elderly patients due to the risk 
of hypoglycemia (<8% or even ≤9% in elderly individuals 
with multiple comorbidities, frailty, and a higher risk of 
hypoglycemia) [88]. 
Smoking
Smoking cessation, optimally during the CR, is one of the 
most important goals of secondary prevention [89]. It is 
important to identify smoking patients not only by medi-
cal interview, which in many cases is insufficient, but also 
by the measurement of carbon oxide levels in exhaled air 
and/or the measurement of urinary nicotine metabolites 
(cotinine). As an adjunctive treatment, the following tools 
may be used in addition to psychological support: nicotine 
replacement therapy (chewing gums, nasal spray, inhaler, 
sublingual tablets), oral preparations (bupropion, varen-
icline), and in some cases electronic cigarettes [90, 91]. 
Electronic cigarettes may be helpful but should be used as 
a bridge to smoking cessation rather than a long-term sub-
stitute [92]. Passive smoking is equally harmful and should 
be reduced [93, 94]. An active search for interventions 
and counseling on smoking cessation is recommended. 
Algorithms can be helpful, including the 5As model (Ask, 
Advise, Assess, Assist, and Arrange) [95, 96].
Low physical activity
Regular physical activity reduces all-cause mortality and 
improves mental health [97–100]. Individuals with a low 
level of physical activity should be encouraged to start 
regular aerobic training, initially at low intensity and grad-
ually increased. In other cases, moderate-intensity exercise 
is recommended. This includes both recreational activity 
(brisk walking, Nordic walking, trekking, jogging, running, 
cycling, cross-country skiing, dancing, skating, rowing, 
swimming) as well as occupational activity (physical work). 
The workload is determined on the basis of the exercise test 
after completion of the CR program [101]. At least 30 to 
60 minutes of moderate physical activity on most days 
of the week are recommended [4, 11, 70, 102]. Vigorous 
aerobic and resistance/strength training is preferable, com-
plemented by whole-body training including stretching, 
balancing, agility, relaxation, and flexibility exercises. An 
effective way to support higher levels of physical activity 
is the use of activity trackers: bands, watches, and mobile 
applications. 
Excessive psychological and emotional stress
Interventions aimed at reducing psychosocial risk factors 
may prevent psychosocial stress, depression, and anxiety, 
thus facilitating behavioral changes as well as improving 
the quality of life and prognosis [52, 103]. In patients with 
hostility, group training may be effective by increasing 
social adjustment as well as improving HR and BP control 
[104].
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